LENZ rallies presbyopia awareness with eyecare professionals ahead of FDA submission
05 Apr 2024
Phase 3
LENZ Therapeutics is clear on the benefits of pre-commercial marketing for its presbyopia eye drops, bolstered by positive Phase 3 news this week. The new
data
back its confidence — and plans to file for FDA approval midyear — in its late-stage candidate and mainstream market potential.
The biotech soft-launched a campaign for eye care professionals in February, and will fully launch mid-month with the addition of 30 more optometry and ophthalmology experts joining the “Eye Am” effort. The awareness
website
uses striking photographs of leading eye care doctors taken by commercial photographer and director Will Strawser, along with statements about the doctors’ excitement and expectations around new presbyopia research.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.